KRAS at Triple Meeting: Erasca wants to one-up RevMed, while Alterome tries a different approach
Revolution Medicines posted strong data on its targeted pancreatic cancer drug Thursday evening, but competition is building at every turn in the KRAS field. RevMed’s game-changing pan-RAS drug Rasonque (daraxonrasib) alongside ...
We haven't written up this one. Endpoints News has the full story — the link below goes straight to it.